Quarterly ResultMay 7, 2026, 04:21 PM
Enliven Q1 Net Loss $23.6M; $452M Cash; ELVN-001 Phase 3 H2 2026
AI Summary
Enliven Therapeutics reported a net loss of $23.6 million for the first quarter of 2026, an improvement from the prior year. The company maintains a strong financial position with $452.4 million in cash, cash equivalents, and marketable securities, providing a cash runway into the first half of 2029. Enliven also provided a business update, confirming expectations for a Phase 1 data update for ELVN-001 mid-2026 and the initiation of the Phase 3 ENABLE-2 pivotal trial in the second half of 2026.
Key Highlights
- Cash, cash equivalents, and marketable securities totaled $452.4 million as of March 31, 2026.
- Cash runway is expected to extend into the first half of 2029.
- Net loss for Q1 2026 was $23.6 million, an improvement from $28.5 million in Q1 2025.
- Net loss per share was $(0.38) in Q1 2026, compared to $(0.57) in Q1 2025.
- R&D expenses decreased to $20.7 million in Q1 2026 from $24.9 million in Q1 2025.
- Initiation of the Phase 3 ENABLE-2 pivotal trial for ELVN-001 is expected in H2 2026.
- Additional Phase 1 data for ELVN-001 from the ENABLE trial is expected mid-2026.